{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:03:22Z","timestamp":1790964202067,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPD"],"published-print":{"date-parts":[[2001,9,1]]},"DOI":"10.2174\/1381612013397366","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T20:10:31Z","timestamp":1111695031000},"page":"1413-1431","source":"Crossref","is-referenced-by-count":59,"title":["Imidazoline Binding Sites in the Endocrine Pancreas: Can They Fulfil Their Potential as Targets for the Development of New Insulin Secretagogues?"],"prefix":"10.2174","volume":"7","author":[{"given":"Noel","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/64927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T09:40:19Z","timestamp":1448012419000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1381-6128&volume=7&issue=14&spage=1413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,1]]},"references-count":0,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2001,9,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612013397366","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2001,9,1]]}}}